Abstract: Objective To investigate the effect of adjuvant therapy with Anluo HuaXian Wan on anti-liver fibrosis in patients with compensated hepatitis B cirrhosis. Methods A total of 106 patients with compensated hepatitis B cirrhosis in the Department of Gastroenterology and Hepatology of Liaocheng Infectious Disease Hospital from May 2020 to May 2022 were selected for the study, the enrolled patients were divided into control group and study group according to random drawing method, 53 cases in each group. Patients in the control group were treated with tenofovir, while patients in the study group were treated with oral Anluo HuaXian Wan as adjuvant therapy. The anti-fibrotic effect, liver function, viral load, levels of various inflammatory cytokines and liver stiffness, and the safety of the drug were evaluated in both groups after 1 year of continuous treatment. Results The total effective rate of treatment was higher in the study group than in the control group, with significant differences compared between groups (P<0.05). There was no difference in the levels of liver fibrosis indexes compared between the two groups of patients before treatment (P>0.05), and the levels of liver fibrosis indexes in the study group were lower than those in the control group after treatment (P<0.05). There was no difference between the liver function indexes and HBV-DNA load levels of patients in the two groups before treatment compared with each other (P>0.05), and the liver function indexes and HBV-DNA load levels of patients in the study group were lower than those of the control group after treatment (P<0.05). There was no difference in the levels of each inflammatory cytokine and liver hardness compared between the two groups before treatment (P>0.05), and the levels of each inflammatory cytokine and liver hardness of patients in the study group were lower than those in the control group after treatment (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05), and no serious adverse reactions occurred in either group. Conclusion The adjuvant therapy of Anluo HuaXian Wan can effectively enhance the anti-liver fibrosis and anti-viral effects, inhibit the inflammatory response, and has a high safety profile, which is worthy of clinical application.

Key words: Anluo Huaxian Wan, compensated hepatitis B cirrhosis, liver fibrosis, inflammatory response, liver function, HBV-DNA load